SH-1028 tablets

DRUG3 trials

Sponsors

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Conditions

Healthy VolunteerNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed Conditions

Nanjing Sanhome Pharmaceutical, Co., Ltd.Healthy Volunteer

Start: 2019-07-31End: 2019-12-31Target: 16Updated: 2019-06-04

Phase 3

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Nanjing Sanhome Pharmaceutical, Co., Ltd.Non-Small Cell Lung Cancer

Start: 2020-01-31End: 2024-01-31Target: 240Updated: 2020-01-27

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

RecruitingNCT06080776

Nanjing Sanhome Pharmaceutical, Co., Ltd.Non-small Cell Lung Cancer

Start: 2023-05-11End: 2031-02-01Target: 242Updated: 2023-10-12